[Clinical response to etiotropic therapy of chronic viral hepatitis C].
Matched patients with chronic hepatitis C (CHC) were treated with monotherapy with intron A, or its combination with ribavirin or pegintron combination with ribavirin. The comparison group consisted of patients with a natural CHC course who received no specific antiviral therapy. The highest treatment efficacy was achieved in use of pegintron with ribavirin. However, this combination was associated with more frequent CNS and skin side effects. Side effects in all the above groups regressed completely for 1-3 months after the treatment.
Gromova
N I
NI
Bogomolov
B P
BP
D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a